TRANSFORM Trial: Overview and Potential Implications

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

TRANSFORMing Cardiovascular Care

TRANSFORM Trial: Overview and Potential Implications 

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve optimal LDL-C levels and reduce cardiovascular risks.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI
    Director, Mount Sinai Fuster Heart Hospital
    Dr. Valentin Fuster Professor of Cardiovascular Medicine
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Dr. Bhatt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Angiowave, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., CellProthera, Cereno Scientific, GlaxoSmithKline, Hims & Hers Health, Inc., Janssen Biotech, Inc., Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio Pharmaceuticals, Inc., PLx Pharma, SFJ Pharmaceuticals, Stasys Medical Corporation, Youngene Therapeutics
    Contracted Research: 89Bio, Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam Pharmaceuticals, Inc, Amarin Corporation plc, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bayer, Beren, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc., Boston Scientific, Bristol Myers Squibb Company, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor Pharma, Inc., Cleerly, CSI, CSL Behring, Eisai Co., Ltd., Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Biotech, Inc., Javelin, Lexicon Pharmaceuticals, Inc., Lilly, Medtronic, Inc., Merck, Moderna, Inc., MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka Pharmaceutical Co., Ltd., Owkin, Pfizer, Inc., PhaseBio Pharmaceuticals, Inc., Philips, PLx Pharma, Recardio, Regeneron Pharmaceuticals, Inc., Roche, Sanofi, SpectraWAVE, Stasys Medical Corporation, Synaptics, The Medicines Company, Vascular Solutions, Youngene Therapeutics
    Patent Beneficiary: Lexicon Pharmaceuticals, Sotagliflozin
    Stock Options: Angiowave, Bristol Myers Squibb Company

    Marc P. Bonaca, MD, MPH
    Director, Vascular Research
    Associate Professor of Medicine
    University of Colorado School of Medicine
    Aurora, CO

    Dr. Bonaca has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Bayer, Merck, Roche Diagnostics

    Matthew J. Budoff, MD, FACC, FAHA
    Investigator, The Lundquist Institute
    Professor of Medicine
    David Geffen School of Medicine at UCLA
    Torrance, CA

    No relevant relationships reported

    David J. Maron, MD
    Director, Preventive Cardiology
    C. F. Rehnborg Professor of Medicine
    Stanford Medicine
    Stanford, CA

    No relevant relationships reported

    Pam R. Taub, MD, FACC, FASPC
    Director, Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
    Division of Cardiovascular Medicine
    UC San Diego Health System
    La Jolla, CA

    Dr. Taub has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amarin, Amgen, Bayer, Boehringer Ingelheim, Esperion, Medtronic, Novartis, Novo Nordisk, Sanofi
    Ownership Interest: Epirium Bio

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Susan Diaz has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Vin Kalathiveetil has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Will Uptegraph has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the impact of newer pharmacologic therapies on LDL-C control and clinical outcomes in patients with hyperlipidemia and established atherosclerotic cardiovascular disease
    • Explore the impact of emerging drug classes and technological advances on the primary prevention of cardiovascular disease
    • Analyze the design of ongoing trials exploring personalized interventions, such as the TRANSFORM trial, and their potential impact on the primary prevention of cardiovascular disease
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, endocrinologists, and nephrologists, as well as nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with cardiovascular disease.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until June 14, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/.075 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-068-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ( 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Cleerly Health, Esperion Therapeutics, Inc., and Lexicon Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jul 2024